The origin of a name that reflects Europe's cultural roots.

**Ancient Greek**

αἷμα [haima] = blood  
αἵματος [haimatos] = of blood  
λόγος [logos] = reasoning

**Scientific Latin**

haematologicus (adjective) = related to blood

**Scientific Latin**

haematologica (adjective, plural and neuter, used as a noun) = hematological subjects

**Modern English**

the hematology journal  
2004 JCR® Impact Factor = 4.192

Haematologica/The Hematology Journal, as the official organ of the European Hematology Association (EHA), aims not only to serve the scientific community, but also to promote European cultural identity.
Information for readers, authors and subscribers

Haematologica/The Hematology Journal (print edition, pISSN 0390-6078, eISSN 1592-8721) publishes peer-reviewed papers on all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the World Association of Medical Editors (WAME) recommendations on publication ethics policies for medical journals (www.wame.org/pubethicrec.htm).

Haematologica/The Hematology Journal publishes editorials, perspectives, research papers, decision making & problem solving papers, review articles, brief reports and scientific letters. Manuscripts should be prepared according to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, prepared by the International Committee of Medical Journal Editors (ICMJE) and fully available online (http://www.icmje.org). Additional papers may be considered for the purely online journal (Haematologica/The Hematology Journal on Internet, eISSN 1592-8721). Because there are no space constraints online, Haematologica/The Hematology Journal will publish several items deemed by peer review to be scientifically sound and mainly useful as educational papers. These will include case reports, irreplaceable images, educational material from scientific meetings, meeting abstracts, and letters to the Editor.

Papers should be submitted online at http://www.haematologica.org/.

Conflict of interests. According to the International Committee of Medical Journal Editors (http://www.icmje.org/#conflicts), “Public trust in the peer review process and the credibility of published articles depend in part on how well conflict of interest is handled during writing, peer review, and editorial decision making”. The journal’s policy is reported in detail online (www.haematologica-thj.org/policy.html).

Galley Proofs and Reprints. Galley proofs should be corrected and returned by email, fax or express delivery within 72 hours. Minor corrections or reasonable additions are permitted; however, excessive alterations will require editorial re-evaluation and will be possibly charged to the authors. Papers accepted for publication will be printed without cost. The cost of printing color figures will be communicated upon request. Reprints may be ordered at cost by returning the appropriate form sent by the Publisher.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Ferrata Storti Foundation. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

Haematologica/The Hematology Journal is published in three printed editions: International (worldwide except Italy, Spain, Portugal and Latin America), Italian (Italy) and Spanish (Spain, Portugal and Latin America). Detailed information about subscriptions is available online: http://www.haematologica-thj.org/subscribe. While access to the online journal is free, online access to additional items of the website http://www.haematologica-thj.org will require either institutional or personal subscription.

Rates of the International edition for the year 2006 are as following:

<table>
<thead>
<tr>
<th></th>
<th>Institutional</th>
<th>Personal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Print edition (including full access to the online CME for personal subscribers)</td>
<td>Euro 350</td>
<td>Euro 150</td>
</tr>
<tr>
<td>Full access to the online CME only</td>
<td>Euro 75</td>
<td></td>
</tr>
</tbody>
</table>

To subscribe to the International edition, please visit our web site http://www.haematologica.org/subscribe or contact: Haematologica/the Hematology Journal Office, Strada Nuova 134, 27100 Pavia, Italy (phone +39.0382.531182, fax +39.0382.27721, E-mail: office@haematologica.org).

Advertisements. Contact the Advertising Manager, Haematologica/The Hematology Journal Office, Strada Nuova 134, 27100 Pavia, Italy (phone +39.0382.531182, fax +39.0382.27721, E-mail: mikimos@haematologica.org).

Disclaimer. Whilst every effort is made by the publishers and the editorial board to see that no inaccurate or misleading data, opinion or statement appears in this journal, they wish to make it clear that the data and opinions appearing in the articles or advertisements herein are the responsibility of the contributor or advisor concerned. Accordingly, the publisher, the editorial board and their respective employees, officers and agents accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion or statement. Whilst all due care is taken to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this journal, should only be followed in conjunction with the drug manufacturer’s own published literature.

Direttore responsabile: Prof. Edoardo Ascari; Autorizzazione del Tribunale di Pavia n. 63 del 5 marzo 1955.

Editing: Medit - Medical Editions, via A. Fogazzaro 5, Voghera, Italy

Image of blood cells on cover: Giorgio Lambertenghi Deliliers, University of Milan, Italy.
Organizing Committee 11th Congress
A. Hagenbeek, Congress President, The Netherlands
P. Huigens, The Netherlands

Scientific Program Committee 11th Congress
H. Döhner, Chair, Germany
T. Barbui, Italy
A. Biondi, Italy
P. Fenaux, France
W.E. Fibbe, The Netherlands
A.R. Green, United Kingdom
C. Mecucci, Italy
I. Pabinger, Austria
I.P. Touw, The Netherlands

EHA Executive Board
E. Hellström-Lindberg, President, Sweden
W.E. Fibbe, President Elect, The Netherlands
E. Montserrat, Past President, Spain
A. Hagenbeek, Treasurer, The Netherlands
I. Roberts, Secretary, United Kingdom

EHA Councilors
E. Berntorp, Sweden
H. Döhner, Germany
P. Fenaux, France
C. Lacombe, France
C. Mecucci, Italy
J.F. San Miguel, Spain

Scientific and Education Committee 11th Congress
M. Alberich Jorda, Spain
M. Björkholm, Sweden
N. Borregaard, Denmark
M. Cavazzana-Calvo, France
E. Cervantes, Spain
J. Cools, Belgium
M.A. Dimopoulos, Greece
A. Engert, Germany
M. Fontenay, France
C. Hershko, Israel
S. Kaasa, Norway
O. Legrand, France
B. Mansouri, Switzerland
J. Melo, United Kingdom
J.M. Ribera, Spain
A. Rosenwald, Germany
C. Schoch, Germany
S. Schulman, Canada
G. Socié, France
E. Stevenson, United Kingdom
A. Trumpp, Switzerland
B. van Camp, Belgium
M.H.J. van Oers, The Netherlands
W.W. van Solinge, The Netherlands

Haematologica/The Hematology Journal
M. Cazzola, Editor, Italy
R. Foà, Editor, Italy

EHA Education Committee
A.R. Green, Chair, United Kingdom
E. Hellström-Lindberg, EHA President, Sweden
D. Jasmin, ESH Representative, France
L. Degos, Project Leader, France
H. Döhner, Project Leader, Germany
E. Berntorp, Sweden
C. Chomienne, France
C. Craddock, United Kingdom
F. Lo Coco, Italy
A. Urbano Isipizua, Spain

European Hematology Association
Executive Office
Westblaak 71, 3012 KE, Rotterdam,
The Netherlands
Tel.: +31 10 436 1760, Fax: +31 10 436 1817
E-mail: info@ehaweb.org,
Website: www.ehaweb.org
Words of welcome

Welcome to Amsterdam, to the 11th Congress of the European Hematology Association. The Scientific Program Committee and the Scientific and Education Committee of the 11th Congress have developed a most attractive program with expert hematologists presenting their timely views in sessions of a different scope covering both benign and malignant hematology. You are invited to participate in high quality Education, Meet-the-Expert, Hematology-in-Focus and Plenary sessions, as well as in challenging Lunch Debates, Clinical Trial Updates and Science-in-Progress sessions.

From the large number of abstracts submitted a challenging program of simultaneous oral sessions and poster sessions has been established. The 6 best abstracts will be presented during the Presidential Symposium. This year, for the second time, a joint EHA-ASH Symposium will take place on Saturday, June 17. A number of meetings of EHA Scientific Working Groups will be held, which will be of interest to many of you.

In addition, 25 Satellite Symposia will run on Super Thursday, covering the State-of-the-Art in experimental and clinical hematology. The Joint Symposium of the European School of Haematology (ESH) and EHA will take place on Friday.

In contrast to previous meetings, the Opening Ceremony will now take place on Friday, June 16, directly followed by the presentation of the José Carreras Lecture by Professor Eliane Gluckman. In the same session, the winners of the EHA-Jose Carreras Foundation Young Investigator Fellowship and the additional EHA Fellowships and Grants will be presented. For the first time a press conference will be held dealing with major topics selected from the presentations given during the Presidential Symposium.

The congress program is accredited for Continuing Medical Education (CME) by the EHA-CME System, which is the new name for the European Council for Accreditation in Hematology (ECAH). Since this European Commission funded project ended in November 2005 EHA assures the continuity in collaboration with many of the original ECAH partners including ESH. EHA and ESH are dedicated to establishing modern hematology in the European curriculum for medical postgraduate education. The scientific program of the 11th Congress of the EHA has also been reviewed and approved for accreditation by the American Medical Association (AMA).

From a social point of view, it goes without saying that Amsterdam is unbeatable in June! The RAI Congress Centre is close to the city center and you should at least expose yourself to one museum (2006 has been appointed as the Rembrandt year). An extensive program for accompanying persons has been developed, visiting places of interest throughout the Netherlands.

Hand in hand with our meeting progressing will be the Dutch National Soccer Team finding its way to the final game in the World Championship Tournament in Germany taking place at the same time. We will have television screens throughout the conference center to keep you posted (not only on the achievements of the Dutch team).

Do not miss our social event in the former Stock Exchange of Amsterdam (1903), the “Beurs van Berlage” (www.beursvanberlage.nl), which takes place on Saturday night, June 17 from 20.30 hours till midnight. Although this year no full buffet dinner will be served, there are plenty of bites and drinks to get you through. An attractive evening program will be presented in a fascinating environment comprising music entertainment, dancing, a big screen showing a live soccer game from the World Championship Tournament in Germany (Italy vs. USA) and additional surprises.

On behalf of the EHA Board, the Scientific Program Committee and the Scientific and Education Committee of the 11th Congress: again welcome to Amsterdam. We trust that this number one hematology congress in Europe will provide you with intense interaction with your peers and induce new creative ideas for your work!

Finally, do not forget to attend the typically Dutch Farewell Lunch Buffet at the end of the congress on Sunday afternoon. We are looking forward to your active participation in the 11th Congress.

Ton Hagenbeek
Congress President

Hartmut Döhner
Chair Scientific and Education Committee
### Poster session I

<table>
<thead>
<tr>
<th>POSTER SESSION</th>
<th>POSTER NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iron diseases</td>
<td>0001-0011 - p. 1</td>
</tr>
<tr>
<td>Anemia / Red blood cells I</td>
<td>0012-0032 - p. 5</td>
</tr>
<tr>
<td>Drug resistance &amp; drug pharmacology</td>
<td>0033-0045 - p. 14</td>
</tr>
<tr>
<td>Molecular diagnostics</td>
<td>0046-0064 - p. 18</td>
</tr>
<tr>
<td>Molecular targeting and gene therapy</td>
<td>0065-0083 - p. 26</td>
</tr>
<tr>
<td>Chronic myeloproliferative disorders I</td>
<td>0084-0104 - p. 32</td>
</tr>
<tr>
<td>Acute myeloid leukemia I</td>
<td>0104-0123 - p. 40</td>
</tr>
<tr>
<td>Acute myeloid leukemia II</td>
<td>0124-0142 - p. 46</td>
</tr>
<tr>
<td>Chronic myeloid leukemia I</td>
<td>0143-0160 - p. 53</td>
</tr>
<tr>
<td>Chronic myeloid leukemia II</td>
<td>0161-0178 - p. 60</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma - Clinical I</td>
<td>0179-0198 - p. 67</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma - Clinical II</td>
<td>0199-0218 - p. 75</td>
</tr>
<tr>
<td>Myeloma and other monoclonal gammopathies I</td>
<td>0219-0238 - p. 82</td>
</tr>
<tr>
<td>Myeloma and other monoclonal gammopathies II</td>
<td>0239-0258 - p. 90</td>
</tr>
<tr>
<td>Chronic lymphocytic leukemia and related disorders - Clinical / Experimental I</td>
<td>0259-0281 - p. 98</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma - Clinical trials</td>
<td>0282-0293 - p. 106</td>
</tr>
<tr>
<td>Allogeneic stem cell transplantation I</td>
<td>0294-0317 - p. 110</td>
</tr>
<tr>
<td>Apoptosis / Transcriptional control / Signalling</td>
<td>0318-0342 - p. 119</td>
</tr>
<tr>
<td>Stem cell transplantation - Experimental</td>
<td>0343-0367 - p. 127</td>
</tr>
<tr>
<td>Infectious diseases, including supportive care</td>
<td>0368-0390 - p. 136</td>
</tr>
<tr>
<td>Thrombosis I</td>
<td>0391-0411 - p. 144</td>
</tr>
<tr>
<td>Bleeding disorders</td>
<td>0412-0429 - p. 151</td>
</tr>
<tr>
<td>Dendritic cells and cellular immunotherapy</td>
<td>0430-0448 - p. 158</td>
</tr>
<tr>
<td>Myelodysplastic syndromes I</td>
<td>0449-0464 - p. 164</td>
</tr>
</tbody>
</table>

### Simultaneous sessions

| Chronic myeloid leukemia                            | 0465-0469 - p. 170 |
| Acute myeloid leukemia                              | 0470-0474 - p. 172 |
| Stem cell biology                                   | 0475-0479 - p. 174 |
| Dendritic cells, vaccination and cellular immunotherapy | 0480-0484 - p. 176 |
| Vascular biology and granulocytes                   | 0485-0489 - p. 178 |
| Multiple myeloma - Clinical                         | 0490-0494 - p. 180 |
| Chronic myeloproliferative disorders                | 0495-0499 - p. 182 |
| Antibodies in the treatment of non-Hodgkin’s lymphoma | 0500-0504 - p. 184 |
| Cancer genetics and cytogenetics in myeloid diseases | 0505-0509 - p. 186 |
| Thrombosis                                          | 0510-0514 - p. 188 |
| Paroxysmal nocturnal hemoglobinuria and Fanconi anemia | 0515-0519 - p. 190 |
| Cell signalling, transcriptional control and apoptosis - I | 0520-0524 - p. 192 |
| Multiple myeloma - Clinical / Experimental          | 0525-0529 - p. 194 |

### Presidential Symposium

| Six best abstracts                                  | 0530-0535 - p. 196 |
Table of Contents

Poster session II

Transfusion medicine 0536-0550 - p. 199
Aplastic anemia 0551-0556 - p. 204
Anemia / Red blood cells II 0557-0576 - p. 206
Cytopathogenetics and molecular cytogenetics 0577-0596 - p. 213
Genomics and proteomics 0597-0611 - p. 221
Non-Hodgkin’s lymphoma - Experimental 0612-0630 - p. 226
Acute myeloid leukemia III 0631-0649 - p. 233
Acute lymphoblastic leukemia 0650-0671 - p. 240
Chronic myeloid leukemia III 0672-0689 - p. 248
Non-Hodgkin’s lymphoma - Clinical III 0690-0709 - p. 254
Non-Hodgkin’s lymphoma - Clinical IV 0710-0727 - p. 262
Myeloma and other monoclonal gammapathies III 0728-0750 - p. 268
Myeloma and other monoclonal gammapathies IV 0751-0773 - p. 277
Chronic lymphocytic leukemia and related disorders - Clinical / Experimental II 0774-0796 - p. 285
Quality of life and cost-effectiveness 0797-0815 - p. 293
Allogeneic stem cell transplantation II 0816-0838 - p. 300
Cytokines and growth factors 0839-0861 - p. 309
Stem cells - Biology 0862-0878 - p. 317
Vascular biology, granulocytes and infectious diseases 0879-0898 - p. 323
Thrombosis II 0899-0921 - p. 330
Platelets / Thrombocytopenia 0922-0937 - p. 337
Myelodysplastic syndromes II 0938-0954 - p. 343
Chronic myeloproliferative disorders II 0955-0974 - p. 349

Simultaneous sessions

Acute myeloid leukemia and myelodysplastic syndromes - Clinical 0975-0979 - p. 357
Acute lymphoblastic leukemia 0980-0984 - p. 359
Hodgkin’s Lymphoma - Clinical trials 0985-0989 - p. 361
Cell signalling, transcriptional control and apoptosis - II 0990-0994 - p. 363
Anemia / Red blood cells 0995-0999 - p. 365
Non-Hodgkin’s lymphoma / Chronic lymphocytic leukemia - Experimental 1000-1004 - p. 367
Pharmacogenetics and molecular targeting 1005-1010 - p. 369
Cancer genetics and cytogenetics in lymphoid diseases 1011-1014 - p. 371
Allogeneic stem cell transplantation - Clinical 1015-1019 - p. 373
Platelets and bleeding disorders 1020-1024 - p. 374
Philadelphia chromosome positive leukemias 1025-1029 - p. 376
Myelodysplastic syndromes 1030-1034 - p. 378
Antibodies in the treatment of chronic lymphocytic leukemia 1035-1039 - p. 380
Clinical studies in non-Hodgkin’s lymphoma 1040-1044 - p. 383

Publication Only

Abstracts published only 1045-1490 - p. 385